3S53

HIV-1 protease triple mutants V32I, I47V, V82I with antiviral drug darunavir in space group P212121

Summary for 3S53

Entry DOI	10.2210/pdb3s53/pdb
Related	2HS1 2IDW 2IEN 3EBZ 3S43 3S54
Descriptor	Protease, (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE, PHOSPHATE ION, ... (5 entities in total)
Functional Keywords	darunavir, hiv/aids, drug resistance, aspartic protease, molecular recognition, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological source	Human immunodeficiency virus 1
Total number of polymer chains	2
Total formula weight	23968.75
Authors	Tie, Y.-F.,Wang, Y.-F.,Weber, I.T. (deposition date: 2011-05-20, release date: 2012-03-21, Last modification date: 2023-09-13)
Primary citation	Tie, Y.,Wang, Y.F.,Boross, P.I.,Chiu, T.Y.,Ghosh, A.K.,Tozser, J.,Louis, J.M.,Harrison, R.W.,Weber, I.T. Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors. Protein Sci., 21:339-350, 2012 Cited by PubMed: 22238126 DOI: 10.1002/pro.2019 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (1.5 Å)

Structure validation